Astec LifeSciences Limited Announces Unaudited Standalone and Consolidated Earnings Results for Second Quarter and Half Year Ended September 30, 2018
October 26, 2018 at 07:59 am EDT
Share
Astec LifeSciences Limited announced unaudited standalone and consolidated earnings results for second quarter and half year ended September 30, 2018. For the quarter, the company reported standalone revenues from operations were INR 1,127.211 million against revenues from operations of INR 959.288 million a year ago. Total income was INR 1,145.737 million against INR 976.139 million a year ago. Profit for the period from continuing operations was INR 115.697 million compared to INR 67.014 million a year ago. Net profit was INR 115.697 million against net profit of INR 67.014 million a year ago. Earnings per share was INR 5.92 per basic share and INR 5.91 per diluted share against basic and diluted per share of INR 3.43 a year ago.
For the half year, the company reported standalone revenues from operations were INR 1,777.177 million against revenues from operations of INR 1,681.993 million a year ago. Total income was INR 1,800.446 million against INR 1,728.380 million a year ago. Profit for the period from continuing operations was INR 130.466 million compared to INR 106.905 million a year ago. Net profit was INR 130.466 million against net profit of INR 106.905 million a year ago. Basic earnings per share was INR 6.68 against INR 5.48 a year ago. Diluted earnings per share was INR 6.66 against INR 5.46 a year ago.
For the quarter, the company reported consolidated revenues from operations were INR 1,127.211 million against revenues from operations of INR 959.289 million a year ago. Total income was INR 1,145.737 million against INR 976.140 million a year ago. Profit for the period from continuing operations was INR 115.728 million compared to INR 67.151 million a year ago. Net profit was INR 115.728 million against net profit of INR 67.151 million a year ago. Basic earnings per share was INR 5.92 against INR 3.44 a year ago. Diluted earnings per share was INR 5.91 against INR 3.43 a year ago.
For the period, the company reported consolidated revenues from operations were INR 1,777.177 million against revenues from operations of INR 1,681.994 million a year ago. Total income was INR 1,800.446 million against INR 1,728.381 million a year ago. Profit for the period from continuing operations was INR 130.583 million compared to INR 107.020 million a year ago. Net profit was INR 130.583 million against net profit of INR 107.020 million a year ago. Basic earnings per share was INR 6.68 against INR 5.42 a year ago. Diluted earnings per share was INR 6.67 against INR 5.41 a year ago.
Astec LifeSciences Limited is an India-based company that is primarily engaged in manufacturing a range of agrochemical active ingredients and pharmaceutical intermediates. The Company operates through the Agrochemicals segment. It manufactures a range of fungicides, insecticides, herbicides, and intermediates for its global customers. The Companyâs products and intermediates includes triazole fungicides, heterocyclic herbicides, sulfonylurea herbicides, synthetic pyrethroids, alkyl and aryl magnesium halides, mixed metal halides, silane derivatives, fluorinated aromatic, aliphatic and heterocyclic intermediates, fluorinated aromatic amines, fluorinated pyridine derivatives, fluorinated aromatic carboxylic acids, fluorinated benzyl alcohols, fluorinated ketones and benzophenones, fluorinated heterocyclic mercaptans, heterocyclic mercaptans, thiopyrimidines, aromatic mercaptans, thorium salts, pyrazaloneâs and heterocyclic sulfonyl chlorides.
ASTEC LIFESCIENCES LIMITED 
